Can-Fite BioPharma Ltd. (TLV:CANF)
1.000
0.00 (0.00%)
Nov 6, 2025, 2:07 PM IDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K USD in the half year ending June 30, 2025, a decrease of -48.47%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm)
$560.00K
Revenue Growth
-16.04%
P/S Ratio
27.15
Revenue / Employee
$112.00K
Employees
5
Market Cap
51.22M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.84B |
| Novolog (Pharm-Up 1966) | 2.04B |
| Ilex Medical | 927.57M |
| Kamada | 571.15M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| BrainsWay | 155.27M |
Can-Fite BioPharma News
- 5 days ago - CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News - GuruFocus
- 7 weeks ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News - GuruFocus
- 7 weeks ago - Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment - GuruFocus
- 2 months ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M - Seeking Alpha
- 2 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 3 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 3 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 3 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire